ERBB2 and breast cancer: When they treated ErbB2 overexpressing breast cancer cells with the ErbB2 targeting monoclonal antibody trastuzumab, the cell viability could be significantly reduced in the 3D cultures, whereas the 2D monolayers were only marginally affected.